In azacitidine treated patients, quality of life of iADL dependent patients was significantly
poorer than iADL independent patients (14.44, 95%CI 1.0-27.9, p=0.04) and did not improve
over time.
Conclusion:
Baseline comprehensive geriatric assessment predicts long term quality of life in MDS
patients. iADL dependent patients have significantly poorer quality of life. Quality of life of
frail MDS patients does not improve with HMA therapy. Further research with larger sample
sizes is needed to better quantify these trends and to guide future management.
SCIENTIFIC PROGRAMME
SESSION I
ETIOLOGY OF MDS
SESSION II
BIOLOGY OF MDS –
GENETIC ABNORMALITIES
SESSION III
BIOLOGY OF MDS:
STEM CELLS AND THE
MICROENVIRONMENT
SESSION IV
DIAGNOSTIC WORKUP
AND PROGNOSTIC
FACTORS IN MDS
SESSION V
SPECIFIC SUBTYPES
OF MDS, BASED ON
MORPHOLOGY AND
MOLECULAR BIOLOGY
SESSION VI
TREATMENT OF MDS
SESSION VII
CURRENT PROGRESS IN
THE TREATMENT OF MDS
SESSION VIII
FUTURE TREATMENTS
AND TREATMENT
STRATEGIES IN MDS
SESSION IX
LATE-BREAKING TALKS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES